A genetic score could sharpen breast cancer risk prediction

NCT ID NCT06922708

First seen Jul 31, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests whether adding a polygenic risk score (PRS) — a measure based on 313 genetic markers — to the standard CanRisk model can improve breast cancer risk prediction and prevention. About 100 women at increased risk will receive genetic counseling, a blood draw, and the PRS result, then answer questionnaires about their understanding and emotional response. The goal is to see if this integrated approach is practical, acceptable, and helpful in a real-world clinic setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Polygenic risk score (PRS) testing integrated into the CanRisk model, alongside standard genetic counseling
What this could lead to
If successful, this could make breast cancer risk prediction more precise, enabling earlier and more personalized prevention strategies for women at higher risk.
What could go wrong
This is a small feasibility study, not a large trial, so it may not prove that PRS improves outcomes. The added psychological impact and the complexity of integrating PRS into routine care are also potential challenges.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Policlinico Universitario Fondazione Agostino Gemelli

    RECRUITING

    Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.